吸入麻醉市场（按产品、应用、最终用户和地区）

吸入麻醉市场规模预计在 2025 年为 14.836 亿美元，预计到 2032 年将达到 21.297 亿美元，2025 年至 2032 年的复合年增长率为 5.3%。

吸入麻醉剂（目前最常用的药物包括氧化亚氮、氟烷、Isoflurane、DESFLURANE和SEVOFLURANE）用于在手术室诱导和维持全身麻醉。吸入麻醉剂是维持麻醉的首选，因为它们可以更精确地控制麻醉状态，价格较低。

市场动态

慢性病盛行率上升、老年人口增长、急诊病例和外科手术干预增加、吸入麻醉需求增加以及 COVID-19（大流行）的爆发是预计在预测期内促进全球吸入麻醉市场增长的关键因素。

例如，2022年8月，主要企业的多医院学名药公司Piramal Pharma Limited旗下重症加护业务宣布在美国市场推出首个硫酸锌注射剂非专利。该产品已获得美国食品药物管理局(FDA)核准为竞争性仿製学名药。其规格有30毫克/10毫升（3毫克/毫升）和25毫克/5毫升（5毫克/毫升）。

本研究的主要特点

• 本报告对全球吸入麻醉市场进行了详细分析，并提供了预测期 2025-2032 的市场规模和年复合成长率(CAGR)，假设 2024 年为基准年。
• 它还揭示了不同领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
• 该报告涵盖了全球吸入麻醉市场的主要企业概况，基于以下参数，例如公司亮点、产品系列、主要亮点、财务表现和策略。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球吸入麻醉市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过用于分析全球吸入麻醉市场的各种策略矩阵来促进决策。

目录：

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 慢性病和人口老化增加
  • 学名药的副作用和日益增长的需求
  • 对新型吸入麻醉剂的需求或使用增加
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 2020 年至 2032 年全球吸入麻醉市场（依产品划分）

• SEVOFLURANE
• DESFLURANE
• Isoflurane
• 氧化亚氮

5. 2020 年至 2032 年全球吸入麻醉市场应用情形

• 介绍
• 维持

6. 2020-2032 年全球吸入麻醉市场（依最终使用者划分）

• 医院
• 门诊手术中心

7. 2020-2032 年全球吸入麻醉市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

第八章 竞争态势

• Abbvie Inc.
• Novartis AG
• Piramal Enterprises Ltd.
• Hikma Pharmaceuticals Plc
• Fresenius SE & CO. KGaA
• Baxter International Inc.
• Troikaa Pharmaceuticals, Ltd.
• Halocarbon Products Corporation
• Jiangsu Hengrui Medicine Co., Ltd.
• Lunan Pharmaceutical Group Co. Ltd.

第九章 章节

• 调查方法
• 关于出版商

Inhalation Anesthesia Market size is estimated to be valued at USD 1,483.6 Mn in 2025 and is expected to reach USD 2,129.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.

Inhalation anesthetics (such as nitrous oxide, halothane, isoflurane, desflurane, and sevoflurane; most commonly used agents in practice today) are used for induction and maintenance of general anesthesia in the operating room. Inhaled anesthetics are preferred for maintenance of anesthesia because they allow a more precise control of the anesthetic state and do so at low cost.

Market Dynamics

Increasing prevalence of chronic disease, growing geriatric (aging) population, increasing number of emergency cases and surgical interventions, increase in demand for inhalation anesthesia, and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global inhalation anesthesia market during the forecast period.

For instance, in August 2022, Piramal Pharma Limited's Critical Care business, a leading Complex Hospital Generics company, announced the First to Market Generic U.S. launch of the Zinc Sulfate Injection. This product is U.S. Food and Drug Administration approved with Competitive Generic Therapy (CGT) designation; an approval pathway intended to enhance market competition for sole source drugs. The injection is available in 30mg/10mL (3mg/mL) and 25mg/5mL (5mg/mL).

Key features of the study

• This report provides in-depth analysis of the global inhalation anesthesia market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global inhalation anesthesia market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Abbvie Inc., Novartis AG, Piramal Enterprises Ltd., Hikma Pharmaceuticals Plc, Fresenius SE & CO. KGaA, Halocarbon Products Corporation, Baxter International Inc., Troikaa Pharmaceuticals, Ltd., Jiangsu Hengrui Medicine Co., Ltd., Lunan Pharmaceutical Group Co. Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global inhalation anesthesia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalation anesthesia market.

Detailed Segmentation

• Global Inhalation Anesthesia Market, By Product
  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Nitrous Oxide
• Global Inhalation Anesthesia Market, By Application
  • Induction
  • Maintenance
• Global Inhalation Anesthesia Market, By End User
  • Hospitals
  • Ambulatory Surgical Centers
• Global Inhalation Anesthesia Market, By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles
  • Abbvie Inc.
  • Novartis AG
  • Piramal Enterprises Ltd.
  • Hikma Pharmaceuticals Plc
  • Fresenius SE & CO. KgaA
  • Baxter International Inc.
  • Troikaa Pharmaceuticals, Ltd.
  • Halocarbon Products Corporation
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Lunan Pharmaceutical Group Co. Ltd.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • High burden of chronic disease and growing geriatric population
  • Side-effects and rise in demand or adoption of generic drugs
  • Increasing demand or use of novel inhalation anesthetic drugs
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Inhalation Anesthesia Market, By Product, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Sevoflurane
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Desflurane
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Isoflurane
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Nitrous Oxide
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

5. Global Inhalation Anesthesia Market, By Application, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Induction
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Maintenance
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Inhalation Anesthesia Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Inhalation Anesthesia Market, By Geography, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)

8. Competitive Landscape

• Abbvie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Piramal Enterprises Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals Plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fresenius SE & CO. KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Troikaa Pharmaceuticals, Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Halocarbon Products Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Jiangsu Hengrui Medicine Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lunan Pharmaceutical Group Co. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us